Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel in metastatic castration-resistant prostate cancer
NCT01866423Phase 2Terminated
- Sponsor
- University of Southern California
- Start
- Oct 2013
- Primary completion
- Jul 2015
- Countries
- 1
01
Overview
Phase 2, open-label trial of orteronel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Southern California. Started Oct 2013; status: terminated.
02
Drugs
orteronel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01866423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01866423.